Articles tagged with: Pomalidomide
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …
Results from a recent Italian Phase 1/2 clinical trial indicate that the combination of Pomalyst, cyclophosphamide, and prednisone is effective and safe in relapsed and refractory multiple myeloma patients.
Overall, 51 percent of patients in the trial responded to the treatment, and the median progression-free survival time was 10.4 months. The median overall survival had not been reached yet; however, 69 percent of patients were alive one year after starting treatment.
The study participants had previously been treated with a median of three prior therapies, and all had received prior …
Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with Revlimid and Velcade.
Specifically, the results show that patients receiving Pomalyst (pomalidomide, Imnovid) in combination with low-dose dexamethasone (Decadron) had higher response rates and longer progression-free and overall survival than patients who received high-dose dexamethasone alone.
High-dose dexamethasone was chosen as the comparator in this study because, according to the study investigators, it was a common rescue …
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid.
The study's results highlight how challenging it can be to find an effective treatment for patients who are “dual refractory” (resistant to both Velcade and Revlimid).
Patients in the study who received either Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …
The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma. The European brand name for the drug is expected to be "Imnovid," although final regulatory approval of that name is still pending.
In the United States, pomalidomide is marketed under the brand name Pomalyst. It was approved earlier this year by the U.S. Food and Drug Administration (FDA) as a new treatment for myeloma.
The EC approved Imnovid for use in combination with dexamethasone (Decadron) in …